Interleukin therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: IL-17 (Interleukin-17) promotes an insulin-sensitized state via up-regulation of reprogramming protein Lin28, 8/November/2016, 10.33 am

Interleukin therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: IL-17 (Interleukin-17) promotes an insulin-sensitized state via up-regulation of reprogramming protein Lin28, 8/November/2016, 10.33 am

Interleukin therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: IL-17 (Interleukin-17) promotes an insulin-sensitized state via up-regulation of reprogramming protein Lin28, 8/November/2016, 10.33 am 150 150 Dr Boomi's Genom-2-Discovery Center

Introduction:

A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis regulates glucose metabolism.” This study was published in the 30 September  2011 issue of the Journal “Cell” [One of the best journals in Biological sciences with an I.F of 28.71]  by Prof Daley GQ, Zhu H, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Interleukin therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: IL-17 (Interleukin-17) promotes an insulin-sensitized state via up-regulation of reprogramming protein Lin28


Significance

Given that (1)  more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) the life-long painful injection/drug treatment is required to treat DM; and (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find a way to induce regeneration of adult β-cells that were lost in DM.


What they say:

Prof. Daley GQ and his team members had shown earlier that loss of Lin28 in muscles promotes insulin resistance and glucose intolerance. 


What we say: Research findings:

This study suggests, for the first time, that IL-17, by increasing the expression of its target gene, it may increase the expression of RNA-binding protein Lin-28. Thereby, it may (1) increase the expression of IGF1R, INSR,and IRS2; (2) enhance tissue repair; (3) promote youthful regenerative capacity; and (4) promote insulin sensitivity. Thus, pharmacological formulations encompassing “IL-17 activators” may be used to treat DM.


Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan L, Interleukin therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: IL-17 (Interleukin-17) promotes an insulin-sensitized state via up-regulation of reprogramming protein Lin28, 8/November/2016, 10.33 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org


Undisclosed information: How IL-17 increases the expression of Lin28

Amount: $200

 

100-guaranteed-to-work-if-not-cash-back

# Research cooperation